Head-to-head evidence
Penpulimab vs Toripalimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Penpulimab
Marketed by Akeso
NCT03866993 · Phase 3 · completed
This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment, with disease progression assessed by an independent radiology committee. Its primary endpoint, progression-free survival, was clearly met, roughly doubling median progression-free survival versus placebo plus chemotherapy.
Toripalimab
Marketed by Coherus BioSciences, Inc. and partners
NCT03856411 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled trial of 465 patients met its primary endpoint: median progression-free survival was 8.4 months with toripalimab plus chemotherapy versus 5.6 months with placebo plus chemotherapy, a highly statistically significant improvement.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT06426511 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Penpulimab's landscape · Toripalimab's landscape